@article{cddd2d07938f46b58b604bc711366ba6,
title = "Efficacy of Sofosbuvir/Ledipasvir in Adolescents With Chronic Hepatitis C Genotypes 1, 3, and 4: A Real-world Study",
abstract = "OBJECTIVES: Sofosbuvir/Ledipasvir (SOF/LDV) has been approved by the European Medicine Agency (EMA) for the treatment of children and adolescents (at least 3 years of age) with chronic hepatitis C (CHC) genotype 1, 3, and 4 infection. The aim of this study was to evaluate the efficacy and safety of SOF/LDV in adolescents (12 to ",
author = "Daniele Serranti and Gabriella Nebbia and Mara Cananzi and Emanuele Nicastro and {Di Dato}, Fabiola and Federica Nuti and Silvia Garazzino and Erika Silvestro and Vania Giacomet and Federica Forlanini and Michele Pinon and Calvo, {Pier Luigi} and Silvia Riva and Icilio Dodi and Cangelosi, {Antonina Marta} and Roberto Antonucci and Silvia Ricci and Elisa Bartolini and Greta Mastrangelo and Sandra Trapani and Matteo Lenge and Paola Gaio and Pietro Vajro and Raffaele Iorio and Lorenzo D'Antiga and Giuseppe Indolfi",
note = "Publisher Copyright: Copyright {\textcopyright} 2020 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine",
year = "2020",
month = jul,
day = "29",
doi = "10.1097/MPG.0000000000002900",
language = "English",
volume = "72",
pages = "95--100",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "1",
}